Craig Lindsley Archives
Sep. 21, 2012—Vanderbilt University and Bristol-Myers Squibb have signed a collaboration agreement for the discovery, development and commercialization of novel therapies acting on the mGluR4 glutamate receptor, known as positive allosteric modulators, or PAMs, for the treatment of Parkinson’s disease.
Mar. 9, 2012—With the addition of a new 18,000-square-foot laboratory to be located within the Cool Springs Life Sciences Center, Vanderbilt University is expanding its research enterprise into Williamson County.
Dec. 15, 2011—The progression of new drug candidates for schizophrenia with partner Janssen Pharmaceutica is the latest evidence that a new collaborative model for drug discovery pioneered at Vanderbilt may help identify and develop innovative candidate drugs for treatment of major brain disorders.
Sep. 30, 2011—Drug-like molecules described by Vanderbilt researchers could lead to Parkinson's treatments with fewer side effects.
Sep. 22, 2011—The discovery of new compounds that work in a fundamentally different way than those in existing schizophrenia medications may allow for more normal function of brain cells involved in schizophrenia.
Sep. 15, 2011—Researchers at Vanderbilt University Medical Center, in collaboration with Seaside Therapeutics in Cambridge, Mass., have achieved a milestone in the development of a potential new treatment for fragile X syndrome, the most common genetic cause of autism.
Aug. 10, 2011—Vanderbilt researchers have identified small molecules that can restore normal protein expression in human colorectal carcinoma cells and prevent invasive cancer growth.
Mar. 11, 2011—Vanderbilt University Medical Center has established a new Center for Neuroscience Drug Discovery to accelerate research that may lead to new treatments for Parkinson's disease, schizophrenia and other disorders of the brain.